Joseph Sargon Joseph1, Vincent Lam2, Manish I Patel3. 1. University of Sydney, Sydney, Australia. 2. Discipline of Surgery, University of Sydney, Sydney, Australia. 3. Department of Urology, Westmead Hospital and Discipline of Surgery, University of Sydney, Sydney, Australia. Electronic address: mpatel@med.usyd.edu.au.
Abstract
CONTEXT: Advanced prostate cancer (PCa) is treated with androgen deprivation therapy (ADT) which results in loss of bone mineral density (BMD) and osteoporosis. OBJECTIVE: To perform a systematic review and meta-analysis of evidence to determine the most effective methods of preventing BMD loss in patients with PCa treated with ADT. EVIDENCE ACQUISITION: A systematic search of the Medline, Embase, and EBM Reviews databases was conducted on July 20, 2016 to identify studies on men who received an intervention to prevent osteoporosis after diagnosis of PCa and treatment with ADT. The Preferred Reporting Items for Systematic Reviews and Meta-analyses statement was followed and the studies found were critically appraised. EVIDENCE SYNTHESIS: Twenty-five studies were included in the review and 13 had quantitative data sufficient for meta-analysis of BMD loss. Bisphosphonates led to a significant improvement in areas assessed: the mean difference was 7.09% (95% confidence interval [CI] 5.05-9.13%; p<0.00001) for lumbar BMD, 4.63% (95% CI 0.87-8.4; p=0.02) for femoral neck BMD, and 3.16% (95% CI 0.09-6.23%; p=0.04) for total hip BMD. Selective estrogen receptor modulators (SERMs) were less effective, exercise studies had inconsistent effects, and denosumab could not be quantitatively analyzed. CONCLUSIONS: Bisphosphonates and denosumab are effective treatments in preventing BMD loss in men with PCa taking ADT. SERMs are a less effective alternative. Exercise programs are insufficient in isolation but have a role as an adjunct for holistic care. PATIENT SUMMARY: In this review we determined the best option for preventing osteoporosis in men with prostate cancer being treated with androgen deprivation therapy. We found that bisphosphonates, denosumab, and selective estrogen receptor modulators (SERMs) were effective, but exercise was not useful in isolation. We conclude that bisphosphonates, denosumab, or SERMs should be used and exercise encouraged.
CONTEXT: Advanced prostate cancer (PCa) is treated with androgen deprivation therapy (ADT) which results in loss of bone mineral density (BMD) and osteoporosis. OBJECTIVE: To perform a systematic review and meta-analysis of evidence to determine the most effective methods of preventing BMD loss in patients with PCa treated with ADT. EVIDENCE ACQUISITION: A systematic search of the Medline, Embase, and EBM Reviews databases was conducted on July 20, 2016 to identify studies on men who received an intervention to prevent osteoporosis after diagnosis of PCa and treatment with ADT. The Preferred Reporting Items for Systematic Reviews and Meta-analyses statement was followed and the studies found were critically appraised. EVIDENCE SYNTHESIS: Twenty-five studies were included in the review and 13 had quantitative data sufficient for meta-analysis of BMD loss. Bisphosphonates led to a significant improvement in areas assessed: the mean difference was 7.09% (95% confidence interval [CI] 5.05-9.13%; p<0.00001) for lumbar BMD, 4.63% (95% CI 0.87-8.4; p=0.02) for femoral neck BMD, and 3.16% (95% CI 0.09-6.23%; p=0.04) for total hip BMD. Selective estrogen receptor modulators (SERMs) were less effective, exercise studies had inconsistent effects, and denosumab could not be quantitatively analyzed. CONCLUSIONS:Bisphosphonates and denosumab are effective treatments in preventing BMD loss in men with PCa taking ADT. SERMs are a less effective alternative. Exercise programs are insufficient in isolation but have a role as an adjunct for holistic care. PATIENT SUMMARY: In this review we determined the best option for preventing osteoporosis in men with prostate cancer being treated with androgen deprivation therapy. We found that bisphosphonates, denosumab, and selective estrogen receptor modulators (SERMs) were effective, but exercise was not useful in isolation. We conclude that bisphosphonates, denosumab, or SERMs should be used and exercise encouraged.
Authors: G Corona; S Filippi; P Comelio; N Bianchi; F Frizza; M Dicuio; G Rastrelli; S Concetti; A Sforza; L Vignozzi; M Maggi Journal: Int J Impot Res Date: 2021-03-21 Impact factor: 2.896
Authors: Celia L Gregson; David J Armstrong; Jean Bowden; Cyrus Cooper; John Edwards; Neil J L Gittoes; Nicholas Harvey; John Kanis; Sarah Leyland; Rebecca Low; Eugene McCloskey; Katie Moss; Jane Parker; Zoe Paskins; Kenneth Poole; David M Reid; Mike Stone; Julia Thomson; Nic Vine; Juliet Compston Journal: Arch Osteoporos Date: 2022-04-05 Impact factor: 2.879
Authors: Alexander Haussmann; Nadine Ungar; Angeliki Tsiouris; Monika Sieverding; Joachim Wiskemann; Karen Steindorf Journal: Int J Behav Med Date: 2020-02
Authors: Maria E Suarez-Almazor; Xerxes Pundole; Gerardo Cabanillas; Xiudong Lei; Hui Zhao; Linda S Elting; Maria A Lopez-Olivo; Sharon H Giordano Journal: JAMA Netw Open Date: 2022-04-01
Authors: Barbara Bressi; Maribel Cagliari; Massimiliano Contesini; Elisa Mazzini; Franco Antonio Mario Bergamaschi; Alfredo Moscato; Maria Chiara Bassi; Stefania Costi Journal: Support Care Cancer Date: 2020-10-29 Impact factor: 3.603